Intelligence · Clinical Development
Pipeline search results
Programs matching “alum” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 30 pipeline programs matching "alum" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Durvalumab
AstraZeneca
Non-Small Cell Lung Cancer
2 trials -
Durvalumab
AstraZeneca
Carcinoma, Non-Small-Cell Lung
1 trial -
Durvalumab
AstraZeneca
Hepatocellular Carcinoma
2 trials -
Durvalumab
AstraZeneca
Locally Advanced Cervical Cancer
1 trial -
Durvalumab
AstraZeneca
Muscle Invasive Bladder Cancer
1 trial -
Durvalumab
AstraZeneca
Non Small Cell Lung Cancer NSCLC
1 trial -
Durvalumab
Arcus Biosciences
Non-Small Cell Lung Cancer
1 trial -
Durvalumab
AstraZeneca
Advanced Hepatocellular Carcinoma
1 trial -
Durvalumab
AstraZeneca
Cancer
1 trial -
Durvalumab + SoC chemotherapy
AstraZeneca
Carcinoma, Non-Small-Cell Lung
1 trial -
Ianalumab
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia
2 trials -
Ianalumab
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
1 trial -
MEDI4736 (Durvalumab)
AstraZeneca
Non-Small-Cell Lung Carcinoma NSCLC
1 trial -
MEDI4736 Placebo, DURVALUMAB
CERO THERAPEUTICS HOLDINGS, INC.
Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients
1 trial -
NI-501; emapalumab, NI-501; emapalumab
Swedish Orphan Biovitrum Pty Ltd
Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).
1 trial -
ianalumab
Novartis Pharmaceuticals
Systemic Lupus Erythematosus
1 trial -
ianalumab s.c. q4w
Novartis Pharmaceuticals
Lupus Nephritis
1 trial -
DURVALUMAB
Fondazione Telethon ETS
Non Small Cell Lung Cancer
1 trial -
DURVALUMAB, Ceralasertib
Istituto Gentili S.r.l.
Stage III NSCLC patients with loco-regional relapse > 12 months from the end of CRT +/- < 3 metastatic lesions after PACIFIC regimen or PACIFIC-like regimens (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab), regardless of PD-L1 status, but without EGFR, HER-2 or MET exon14 skipping mutations, ALK, ROS1, RET or NTRK rearrangements.
1 trial -
Durvalumab
United Therapeutics Europe Ltd
Stage IB Hepatocellular Carcinoma AJCC v8
1 trial -
Durvalumab
Syndax Pharmaceuticals
Unresectable Intrahepatic Cholangiocarcinoma
1 trial -
Durvalumab + Oleclumab
MedImmune
Stage III Non-small Cell Lung Cancer
1 trial -
TREMELIMUMAB, DURVALUMAB
The George Institute
MSS and MSI colorectal and endometrial tumors
1 trial -
ZZ-IT-ICI-HCC 1line-023
Second Affiliated Hospital of Soochow University
Liver Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.